hVIVO strengthens Board with appointment of Richard Cotton as Non-Executive Director Seasoned life sciences executive with extensive Board and financial expertise
Traders Cafe with Zak Mir: Bulletin Board Heroes, Monday 15th December 2025
Zak Mir takes a charting look at some of the most closely followed small caps on the London Stock Exchange. Today’s charts are FTSE 100, DAX, Dow, Bitcoin, Ethereum, Gold, Ajax,
Traders Cafe with Zak Mir: Bulletin Board Heroes, Weekend Edition, Sunday 14th December 2025
Zak Mir takes a charting look at some of the most closely followed small caps on the London Stock Exchange. Today’s charts are FTSE 100, DAX, Dow, Bitcoin, Ethereum, Gold,
Shore Capital Reaffirms Buy Rating on hVIVO Despite Share Price Weakness
Shore Capital has maintained its Buy rating on hVIVO PLC, the specialist contract research organisation, with a fair value assessment of 25 pence per share.
hVIVO plc (AIM: HVO) plays key role in $9.2bn Cidara takeover by MSD
hVIVO plc has highlighted a major validation of its clinical capabilities after its client Cidara Therapeutics agreed to be acquired by pharmaceutical giant MSD in a deal worth approximately $9.2
RNS Hotlist with Zak Mir: WCAP, HVO, POLB, ZPHR, GRX, ASTR, ZEN, GEX & CMCX
WeCap (WCAP): Peel Hunt have reduced their holding from 18% to 14%.
hVIVO plc (AIM: HVO) secures £5m+ in new clinical trial contracts
hVIVO plc has announced that its German subsidiary, CRS, has landed more than £5 million in new contracts since September, driven in large part by two returning mid-sized German pharmaceutical
hMPV Interview with Guy Boivin & hVIVO’s Chief Scientific Officer
Join us for an insightful conversation on hMPV featuring our Chief Scientific Officer, Dr Andrew Catchpole and Guy Boivin, a professor from Laval University and one of the founding fathers
hVIVO plc: Diversification in Action as 2026 Growth Beckons
After a turbulent year for the clinical research sector, hVIVO plc (AIM: HVO) has found itself back in penny-stock territory. Its share price, which stood at 29.8 GBX in November
hVIVO plc: Diversification in Action as 2026 Growth Beckons
After a turbulent year for the clinical research sector, hVIVO plc (AIM: HVO) has found itself back in penny-stock territory. Its share price, which stood at 29.8 GBX in November
hVIVO plc (AIM: HVO) Positive data from novel human challenge models
Positive data from multiple novel human challenge models hVIVO presentations made at influential ESWI and World Vaccine Congress Europe conferences
hVIVO plc (AIM: HVO) Presentation at Jefferies Healthcare Conference
hVIVO to present at Jefferies Global Healthcare Conference